|
C1ORF124 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62436730732907E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.4335977677481E-11 |
| Normal-vs-Stage2 |
6.0988999961431E-08 |
| Normal-vs-Stage3 |
9.32587340685131E-15 |
| Normal-vs-Stage4 |
3.73034936274053E-14 |
| Stage1-vs-Stage2 |
5.502200E-01 |
| Stage1-vs-Stage3 |
7.620100E-02 |
| Stage1-vs-Stage4 |
4.901800E-03 |
| Stage2-vs-Stage3 |
1.009420E-01 |
| Stage2-vs-Stage4 |
8.479700E-03 |
| Stage3-vs-Stage4 |
2.145200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.11022302462516E-16 |
| Normal-vs-AfricanAmerican |
4.12870000000565E-05 |
| Normal-vs-Asian |
2.31550001394965E-10 |
| Caucasian-vs-AfricanAmerican |
3.241600E-01 |
| Caucasian-vs-Asian |
7.987800E-01 |
| AfricanAmerican-vs-Asian |
3.078000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.11022302462516E-16 |
| Normal-vs-Female |
1.62458935193399E-12 |
| Male-vs-Female |
1.340830E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.86259896395313E-11 |
| Normal-vs-Age(41-60Yrs) |
1.11022302462516E-16 |
| Normal-vs-Age(61-80Yrs) |
4.86366502627789E-12 |
| Normal-vs-Age(81-100Yrs) |
2.679800E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.177800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.640800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.490600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.766600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.789600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.848600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.597000E-04 |
| Classical-VS-Follicular |
6.669400E-01 |
| Classical-VS-Other |
1.152030E-01 |
| Classical-VS-Normal |
1.96419991382868E-10 |
| Tall-VS-Follicular |
5.257600E-03 |
| Tall-VS-Other |
8.904200E-01 |
| Tall-VS-Normal |
1.11244347067441E-13 |
| Follicular-VS-Other |
1.581410E-01 |
| Follicular-VS-Normal |
1.43089984305789E-11 |
| Other-VS-Normal |
9.90530000000156E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.66133814775094E-16 |
| Normal-vs-N1 |
9.38027433505795E-12 |
| N0-vs-N1 |
2.901600E-01 |
|
|
